Arabic Arabic English English French French German German
dark

Overcoming the Treatment-Risk Paradox for Intensive Blood Pressure Care

Patients most likely to benefit from intensive systolic blood pressure treatment (SBP) versus standard treatment to reduce cardiovascular disease (CVD) may also be at risk for adverse events (AE). In an editorial discussing those risks and clinical decisions to pursue intensive care, Joseph Diamond, MD, of The Feinstein Institutes for Medical Research published an editorial in the Journal of American College of Cardiology (JACC). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Midatech Pharma PLC Announces Results for the Year Ended 31 December 2020

Next Post

Hemogenyx Pharmaceuticals PLC Announces Final Results

Related Posts
Total
0
Share